NorthWest Biotherapeutics Inc (NWBO)

[Nick119]

Stumbled across this article.. has this been shared before?

https://www.mdpi.com/2072-6694/13/1/32/htm#B164-cancers-13-00032

A lot of good information in here, confirming the efficacy of dendritic cell vaccinations... And I believe a lot of the information is based on nwbio trial.

This is great evidence here.. And the reference links to LM Liau :

"In the design of larger RCTs with a control arm, clinical researchers have run into new problems. GBM is a deadly disease. The first interest of the patient is the prolongation of a good-quality life. As DC vaccination has already been shown to significantly prolong long-term OS with a good quality of life, it eventually became unethical to prevent patients in the control arm from being given this innovative fourth anti-GBM immunotherapy modality. Therefore, some RCTs published with PFS as the primary endpoint used a cross-over protocol from the control group to the DC vaccination group, either structurally within the trial design (EudraCT 2009-018228-14) [151] or after reaching the primary end-point (NCT00045968) [160]. By doing so, the OS assessment was, in fact, no longer controlled. In the former study, stratification of RPA classification was used. In the latter study, stratification for MGMT methylation was used."